PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) — via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community.
Related news for (PXMD)
- PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
- PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
- PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
- Threshold List Stocks with Upcoming Catalysts
- PaxMedica Meets Key PAX-101 Development Milestone and May Submit NDA